Bright Peak Therapeutics key facts
as of Oct 2026- Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases.
- It has raised $244.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($90.0M) in Jun 2024.
- Notable investors include Fidelity Management & Research Company, RA Capital Management, KB Investment, Alexandria Venture Investments, BlackRock — 12 tracked in total.
- 2 institutional filers report fund marks on Bright Peak Therapeutics across 39 filings.
- Bright Peak Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently Jun 2024 ($90.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·The complete investor list: 12 names
- ·Watch Bright Peak Therapeutics: the Monday email on marks, rounds and moves
Institutional fund marks on Bright Peak Therapeutics
2 filers · latest Jul 20262 SEC-registered funds reported 39 fair-value marks on Bright Peak Therapeutics between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Bright Peak Therapeutics funding rounds
2 roundsWho backs Bright Peak Therapeutics
12+Recent activity
In the last 90 days, Bright Peak Therapeutics's record added 9 institutional fund marks (latest period Jul 2026).
How much has Bright Peak Therapeutics raised?
Bright Peak Therapeutics has raised $244 million across 2 recorded rounds since 2021. The largest was a $90 million Series C in Jun 2024.
Bright Peak Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently in Jun 2024 ($90 million sold to 21 investors).
Institutional holders and vehicles
2 SEC-registered funds reported 39 fair-value marks on Bright Peak Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Bright Peak Therapeutics investors
12 investors are on record for Bright Peak Therapeutics, including Fidelity Management & Research Company, RA Capital Management, KB Investment and Alexandria Venture Investments. By type, the record holds 4 venture capital firms, 3 asset managers and 1 private equity firm. The Series C in Jun 2024 drew 9 investors.
About Bright Peak Therapeutics
Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. The company develops immuno-cytokines with pharmacological properties that allow tissue and cell-specific targeting through cytokine payload with the added potential for enhanced efficacy, enabling doctors to improve treatment outcomes and quality of life for patients.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Allschwil, Switzerland
- Founded
- 2017
- Employees
- 57
- Website
- brightpeaktx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.